Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 197.75 USD -1.76% Market Closed
Market Cap: 10.1B USD
Have any thoughts about
Charles River Laboratories International Inc?
Write Note

Net Margin
Charles River Laboratories International Inc

10.2%
Current
11%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.2%
=
Net Income
413.1m
/
Revenue
4.1B

Net Margin Across Competitors

Country US
Market Cap 10.1B USD
Net Margin
10%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.2B USD
Net Margin
14%
Country US
Market Cap 170.9B USD
Net Margin
18%
Country KR
Market Cap 67.8T KRW
Net Margin
24%
Country CH
Market Cap 38.5B CHF
Net Margin
9%
Country US
Market Cap 38.6B USD
Net Margin
22%
Country US
Market Cap 36.5B USD
Net Margin
9%
Country US
Market Cap 26.7B USD
Net Margin
21%
Country US
Market Cap 23.2B USD
Net Margin
17%
Country US
Market Cap 23B USD
Net Margin
21%
No Stocks Found

Charles River Laboratories International Inc
Glance View

Market Cap
10.1B USD
Industry
Life Sciences Tools & Services

Charles River Laboratories International Inc. is a leading provider of essential research services and products that support the global clinical development of new drugs. Founded in 1947, the company has evolved from a small laboratory in Massachusetts to a formidable player within the biotech and pharmaceutical sectors. Its comprehensive suite of offerings includes preclinical and clinical laboratory services, along with a range of research models that help organizations like pharmaceutical companies and academic institutions navigate the complexities of drug development. By partnering with clients from early-stage discovery through to advanced trials, Charles River plays a pivotal role in bringing innovative therapies to market while maintaining a strong commitment to animal welfare and ethical research practices. As an investment opportunity, Charles River Laboratories stands out due to its solid financial performance, buoyed by a strategic focus on expanding its capabilities and services. The company has shown robust revenue growth over the years, driven by increasing demand for outsourced laboratory services, especially as the biotech landscape becomes more competitive. With a dedicated management team and a continual investment in technology and infrastructure, Charles River is well-positioned to capitalize on the rising need for more efficient drug development processes. Investors can take confidence from the company's strong market presence, consistent execution, and strategic acquisitions that enhance its service offerings, making it a compelling choice for those looking to invest in the healthcare space.

CRL Intrinsic Value
229.6 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.2%
=
Net Income
413.1m
/
Revenue
4.1B
What is the Net Margin of Charles River Laboratories International Inc?

Based on Charles River Laboratories International Inc's most recent financial statements, the company has Net Margin of 10.2%.